Cargando…
Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence
CTLA-4 is an inhibitory immune checkpoint receptor and a negative regulator of anti-tumor T-cell function. This study is aimed for a comparative analysis of CTLA-4(+) cells between different tumor entities. To quantify CTLA-4(+) cells, 4582 tumor samples from 90 different tumor entities as well as 6...
Autores principales: | Dum, David, Henke, Tjark L. C., Mandelkow, Tim, Yang, Cheng, Bady, Elena, Raedler, Jonas B., Simon, Ronald, Sauter, Guido, Lennartz, Maximilian, Büscheck, Franziska, Luebke, Andreas M., Menz, Anne, Hinsch, Andrea, Höflmayer, Doris, Weidemann, Sören, Fraune, Christoph, Möller, Katharina, Lebok, Patrick, Uhlig, Ria, Bernreuther, Christian, Jacobsen, Frank, Clauditz, Till S., Wilczak, Waldemar, Minner, Sarah, Burandt, Eike, Steurer, Stefan, Blessin, Niclas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162915/ https://www.ncbi.nlm.nih.gov/pubmed/35091676 http://dx.doi.org/10.1038/s41374-022-00728-4 |
Ejemplares similares
-
BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
por: Bady, Elena, et al.
Publicado: (2023) -
Prognostic role of proliferating CD8(+) cytotoxic Tcells in human cancers
por: Blessin, Niclas C., et al.
Publicado: (2021) -
Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma
por: Lennartz, Maximilian, et al.
Publicado: (2021) -
Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms
por: Blessin, Niclas C., et al.
Publicado: (2020) -
Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors
por: Menz, Anne, et al.
Publicado: (2021)